Skip to main content

Advertisement

SpringerLink
Log in

Improving outcomes for patients with chronic hepatitis B

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

The ultimate goal in managing patients with chronic hepatitis B (CHB) is to improve long-term outcomes by decreasing deaths and liver transplantation procedures due to hepatitis B virus (HBV)-related cirrhosis and hepatocellular carcinoma. Active intervention and vaccination of individuals susceptible to HBV infection are key steps to decrease the risk of this global public health problem. Large studies have demonstrated that long-term outcomes of CHB are tied to serum levels of HBV DNA. New oral treatments, characterized by potent antiviral effects, good tolerability, improved histology, stable seroconversion, and minimal resistance, are available. Long-term data with oral medications have shown decreased rates of liver cancer development, liver disease reversal, and progression to liver failure. Pegylated interferon trials have demonstrated modest rates of hepatitis B e antigen seroconversion and improved histology after treatment. This paper describes ways to improve outcomes of CHB using vaccines, interferon, lamivudine, adefovir, and newer agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97–107.

    Article  PubMed  CAS  Google Scholar 

  2. Gish RG, Gadano AC: Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006, in press.

  3. Ganem D, Prince AM: Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004, 350:1118–1129.

    Article  PubMed  CAS  Google Scholar 

  4. World Health Organization: Hepatitis B. Fact Sheet No. 204. http://www.who.int/mediacentre/factsheets/fs204/en. Accessed August 2, 2006.

  5. Dienstag JL, Cianciara J, Karayalcin S, et al.: Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003, 37:748–755.

    Article  PubMed  CAS  Google Scholar 

  6. Fung SK, Wong F, Hussain M, Lok AS: Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004, 11:432–438.

    Article  PubMed  CAS  Google Scholar 

  7. Bartholomeusz A, Locarnini SA: Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liv Dis 2006, 162–170.

  8. Fung SK, Andreone P, Han SH, et al.: Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005, 43:937–943.

    Article  PubMed  CAS  Google Scholar 

  9. Hoofnagle JH, DiBisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997, 336:347–356.

    Article  PubMed  CAS  Google Scholar 

  10. Cihlar T, Lin DC, Pritchard JB, et al.: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999, 56:570–580.

    PubMed  CAS  Google Scholar 

  11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673–2681.

    Article  PubMed  CAS  Google Scholar 

  12. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: CDER priority drug and biologic approvals in calendar year 2005. http://www.fda.gov/cder/rdmt/InternetPriority05.htm. Accessed August 4, 2006.

  13. World Health Organization: Hepatitis B vaccines. WHO position paper. Weekly epidemiological record 2004, 79:255–263. 79:255–263. http://www.who.int/wer. Accessed August 4, 2006.

    Google Scholar 

  14. Zuckerman JN: Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006, 78:169–177.

    Article  PubMed  CAS  Google Scholar 

  15. Chang MH, Chen CJ, Lai MS, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855–1859.

    Article  PubMed  CAS  Google Scholar 

  16. Lok ASF, McMahon BJ: Chronic hepatitis B: update of recommendations. Hepatology 2004, 39:857–861.

    Article  PubMed  Google Scholar 

  17. Zarski, JP, Marcellin P, Leroy V, et al.: Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol 2006, 45:355–360.

    Article  PubMed  Google Scholar 

  18. Fattovich G: Natural history of hepatitis B. J Hepatol 2003, 39:S50–S58.

    Article  PubMed  Google Scholar 

  19. Manesis EK, Papatheodoridis GV, Sevastianos V, et al.: Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003, 98:2261–2267.

    PubMed  CAS  Google Scholar 

  20. Keeffe EB, Dieterich DT, Han SHB, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936–962.

    Article  PubMed  CAS  Google Scholar 

  21. Chen CJ, Yang HI, Su J, et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65–73.

    Article  PubMed  CAS  Google Scholar 

  22. Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678–686.

    Article  PubMed  Google Scholar 

  23. Chen G, Lin W, Shen F, et al.: Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006, 101:1797–1803.

    Article  PubMed  Google Scholar 

  24. Yuen MF, Yuan HJ, Wong DKH, et al.: Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005, 54:1610–1614.

    Article  PubMed  Google Scholar 

  25. Mommeja-Marin H, Mondou E, et al.: Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003, 37:1309–1319.

    Article  PubMed  Google Scholar 

  26. Liaw YF, Sung JJY, Chow WC, et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521–1531.

    Article  PubMed  CAS  Google Scholar 

  27. Schiff E, Lai CL, Hadziyannis S, et al.: Adefovir dipivoxil 10 mg (ADV) for the treatment of chronic hepatitis B in patients pre-liver transplantation with lamivudine-resistant HBV [abstract]. Hepatology 2003, 38:161A.

    Article  Google Scholar 

  28. Locarnini S, Hatzakis A, Heathcote J, et al.: Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004, 9:679–693.

    PubMed  CAS  Google Scholar 

  29. Lau GKK, Piratvisuth T, Luo KX, et al.: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682–2694.

    Article  PubMed  CAS  Google Scholar 

  30. Marcellin P, Lau GKK, Bonino F, et al.: Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206–1217.

    Article  PubMed  CAS  Google Scholar 

  31. Dienstag JL, Schiff ER, Wright TL, et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256–1263.

    Article  PubMed  CAS  Google Scholar 

  32. Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999, 29:889–896.

    Article  PubMed  CAS  Google Scholar 

  33. Marcellin P, Chang TT, Lim SG, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808–816.

    Article  PubMed  CAS  Google Scholar 

  34. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800–807.

    Article  PubMed  CAS  Google Scholar 

  35. Marcellin P, Chang T, Lim S, et al.: Increasing serologic, virologic, and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAg(+) chronic hepatitis B patients. J Hepatol 2005, 42(Suppl 2):31–32.

    Google Scholar 

  36. Seifer M, Hamatake RK, Colonno RJ, Standring DN: In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998; 42:3200–3208.

    PubMed  CAS  Google Scholar 

  37. Chang TT, Gish RG, de Man R, et al.: A comparison of entecavir and lamivudine for HBeAg-positvie chronic hepatitis B. N Engl J Med 2006, 354:1001–1010.

    Article  PubMed  CAS  Google Scholar 

  38. Lai CL, Shouval D, Lok AS, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011–1020.

    Article  PubMed  CAS  Google Scholar 

  39. Gish RG, Chang TT, de Man RA, et al.: Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022) [abstract]. Hepatology 2005, 42(Suppl 1):267A.

    Google Scholar 

  40. Poordad F, Dieterich DT, Min AD, et al.: Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027). Presented at Digestive Diseases Week. Los Angeles, CA. May 20–25, 2006; abstract T1851.

  41. Lai CL, Leung N, Teo EK, et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis Be antigen-positive chronic hepatitis B. Gastroenterology 2005, 129:528–536.

    PubMed  CAS  Google Scholar 

  42. Lai CL, Gane E, Liaw YF, et al.: Telbivudine (LdT) vs lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial [abstract]. Hepatology 2005, 42(Suppl 1):748A

    Google Scholar 

  43. Standring DN, Seifer M, Patty A, et al.: HBV resistance determination from the telbivudine GLOBE registration trial. Presented at the 41st Annual meeting of the European Association for the Study of the Liver. Vienna, Austria. April 26–30, 2006; abstract 514.

  44. Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 2006, 44(Suppl 1): 222A.

    Google Scholar 

  45. Locarnini S: Relevance of HBV mutations in severity and progression of chronic hepatitis B. J Gastroenterol Hepatol 2004, 19:S108–S112.

    Article  Google Scholar 

  46. Gilead Sciences: Hepsera (adefovir dipivoxil). Prescribing information. Foster City, CA: Gilead; April 2006.

    Google Scholar 

  47. Borroto-Esoda K, Arterburn S, Snow A, et al.: Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients. Presented at the 41st Annual meeting of the European Association for the Study of the Liver. Vienna, Austria: April 26–30, 2006; abstract 483.

  48. Colonno R, Rose R, Levine S, et al.: Entecavir two year resistance update: no resistance observed in nucleoside-naïve patients and low frequency resistance emergence in lamivudine refractory patients [abstract]. Hepatology 2005, 42(Suppl 1):573A.

    Google Scholar 

  49. Colonno RJ, Rose RE, Pokornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside-naive patients while resistance emergence increases over time in lamivudine-refractory patients. Hepatology 2006, 44(Suppl 1):229A–230A.

    Google Scholar 

  50. Perrillo R, Schiff E, Yoshida E, et al.: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000, 2:129–134.

    Article  Google Scholar 

  51. Sherman M, Yurdaydin C, Sollano J, et al.: Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039–2049.

    Article  PubMed  CAS  Google Scholar 

  52. Fung SK, Chae SB, Fontana RJ, et al.: Virologic response and resistance to adefovir in patients with chronic hepatitis B. Hepatology 2006, 44:283–290.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Transplantation, Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, 2340 Clay Street, Room 223, San Francisco, CA, 94115, USA

    Robert G. Gish

Authors
  1. Robert G. Gish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert G. Gish.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gish, R.G. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep 9, 14–22 (2007). https://doi.org/10.1007/s11894-008-0016-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-008-0016-9

Keywords

Search

Navigation